S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
复制标题
S-腺苷-L-蛋氨酸治疗慢性肝病：系统评价和荟萃分析。
DOI：
10.1371/journal.pone.0122124
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Liu Q
中科院分区：
文献类型：
--
作者：
Guo T;Chang L;Xiao Y;Liu Q
众所周知，S-腺苷-L-甲硫氨酸 (SAMe) 是甲基转移酶反应中的主要甲基供体，补充 SAMe 可以恢复肝脏谷胱甘肽 (GSH) 沉积并减轻肝损伤。然而，SAMe 疗法在慢性肝病中的有效性尚未得到充分解决。我们检索了全球认可的电子数据库，包括 PubMed、Cochrane 数据库和 EMBASE，检索过去 20 年发表的相关慢性肝病随机对照试验（RCT）。然后，我们对符合纳入标准的入组试验进行了系统回顾和荟萃分析。结果显示，本研究纳入了来自 11 项研究的 12 项随机对照试验，共检查了 705 名患者。对于肝功能，从数据合成和独立比较中获得的某些结果表明总胆红素（TBIL）和天冬氨酸转氨酶（AST）水平之间存在显着差异。然而，没有研究发现丙氨酸转氨酶 (ALT) 水平存在显着差异。对不良事件和长期预后的分析也表明 SAMe 组和安慰剂组之间没有显着差异。在对孕妇和儿童进行的亚组分析中，纳入的一些数据表明瘙痒评分存在显着差异。此外，关于熊去氧胆酸 (UDCA) 和更强的 neo-minophagen C (SNMC) 的结果表明，这两种治疗方法在某些慢性肝病中比 SAMe 更有效。这些研究结果表明，SAMe 由于其安全性，可以用作改善肝功能的药物治疗方案的基础。然而，SAMe 在治疗某些慢性肝病方面也表现出有限的临床价值。
It has been well established that S-adenosyl-L-methionine (SAMe) is the principal methyl donor in methyltransferase reactions and that SAMe supplementation restores hepatic glutathione (GSH) deposits and attenuates liver injury. However, the effectiveness of SAMe therapy in chronic liver disease has not been adequately addressed. We searched globally recognized electronic databases, including PubMed, the Cochrane Database and EMBASE, to retrieve relevant randomized controlled trials (RCTs) of chronic liver disease published in the past 20 years. We then performed a systematic review and meta-analysis of the enrolled trials that met the inclusion criteria.The results showed that twelve RCTs from 11 studies, which examined 705 patients, were included in this research. For liver function, certain results obtained from data synthesis and independent comparisons demonstrated significant differences between the levels of total bilirubin (TBIL) and aspartate transaminase (AST). However, no studies identified significant differences regarding alanine transaminase (ALT) levels. An analysis of the adverse events and long-term prognosis also indicated no significant differences between the SAMe and the placebo groups. In a subgroup analysis of gravidas and children, several of the included data indicated that there was a significant difference in the pruritus score. Furthermore, the results regarding ursodeoxycholic acid (UDCA) and stronger neo-minophagen C (SNMC) indicated that both treatments were more effective than SAMe was in certain chronic liver diseases. These findings suggest that SAMe could be used as the basis of a medication regimen for liver function improvement because of its safety. However, SAMe also demonstrated limited clinical value in the treatment of certain chronic liver diseases.
登录
查看更多内容
影响因子：
3.7
作者：
Filipowicz M;Bernsmeier C;Terracciano L;Duong FH;Heim MH
通讯作者：
Heim MH
影响因子：
3.9
作者：
Loenen, WAM
通讯作者：
Loenen, WAM
DOI：
10.1111/j.1471-0528.1998.tb09976.x
发表时间：
1998-11-01
期刊：
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY
影响因子：
--
作者：
Nicastri, PL;Diaferia, A;Fanelli, M
通讯作者：
Fanelli, M
DOI：
10.1016/0197-2456(86)90046-2
发表时间：
1986-09-01
期刊：
CONTROLLED CLINICAL TRIALS
影响因子：
--
作者：
DERSIMONIAN, R;LAIRD, N
通讯作者：
LAIRD, N
DOI：
10.1111/j.1530-0277.2011.01547.x
发表时间：
2011-11
期刊：
Alcoholism, clinical and experimental research
影响因子：
--
作者：
Medici V;Virata MC;Peerson JM;Stabler SP;French SW;Gregory JF 3rd;Albanese A;Bowlus CL;Devaraj S;Panacek EA;Richards JR;Halsted CH
通讯作者：
Halsted CH